Advice Pool
#1 in Business Subscribe Email Print

You are here: Home > Legal > Legal > Say What? You Don't Have An Estate Plan . . . !

Tags

  • pharmaceutical
  • cycle
  • companies involved
  • other estate

  • Links

  • Colorado River Fishing
  • Over The Counter Stocks - Definition and Overview
  • Do We Get Enough Vitamins From Our Diet Or Are Supplements Necessary?
  • Advice Pool - Say What? You Don't Have An Estate Plan . . . !

    If you haven't taken the time to prepare your estate plan, you're not alone. According to a survey conducted by FindLaw.com, a whopping 55% of Americans haven't even taken the time to have a will prepared, and 67% don't have a living will in c
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    ase they become incapacitated or terminally ill.

    But that's not all! The Findlaw.com survey also found that even those who did have a will generally did not keep it updated. In fact, nearly 40% said they had not updated their will within the
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    ast five years.

    It's not as though people are unaware of the need to plan their estates. Estate planners and many other professionals have preached the need for wills, and other estate planning documents for years. Most recently, the Terri Sc
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    hiavo case brought the issue of living wills to national prominence. Yet, despite the brief surge in demand for living wills and other estate planning documents during that time, most Americans seem to have lapsed back into complacency about p
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    anning for their incapacity or death.

    "That, in itself, may be the problem," says Attorney Alan H. Berman of Hartford, Connecticut. People don't like talking about death and dying, especially when they're talking about themselves or their lov
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    ed ones." Attorney Berman says that many of his clients put off having a will prepared until the very last minute. "I get a lot of calls just before they have to get on an airplane," he says. "Then they know they can't put it off any longer."
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    Death and dying are nobody's favorite topics, to be sure. But, there seems to be more to it than that. The Allianz American Legacies Study, which was sponsored by the Allianz Life Insurance Company, surveyed 2,627 people of all age groups "to
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    identify how they define leaving a legacy and how families are communicating about these sensitive issues today."

    One of the interesting - and, probably, most revealing - facts to come out of the Allianz American Legacies Study was this - sen
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    ors and baby boomers both ranked money last on their list of important estate planning issues. Ranked ahead of money was the idea of leaving a legacy which, according to the study, "captures all facets of an individual's life - including their
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    family traditions and history, sharing stories, values and wishes."

    Attorney Berman agrees with the assessment of the Allianz American Legacies Study. "From my experience," he says, "people seem to clam up as soon as you start talking about
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    oney. They'd rather talk about their family history or certain mementos - prized personal possessions that might not have a lot of monetary value but certainly have a lot of sentimental value."

    Another reason why many people procrastinate whe
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    n it comes to estate planning is their feeling that they don't have enough money to bother with an estate plan. However, as Attorney Berman is quick to point out, "estate planning is not just about money. In fact, it's about taking care of you
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    loved one's needs in the event you can't do it on your own. Money is often a means to an end, but the end is often the well-being of loved ones." That's the "legacy" that seems to motivate most people when it comes to estate planning.

    If we
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    are to learn anything from the Allianz American Legacies Study, it would seem to be that estate planners should direct their efforts toward "legacy" planning rather than "inheritance" planning. Unfortunately, most estate planners spend their t
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    me learning about the intracacies of the estate tax laws and the probate laws when they should be learning about assessing a client's attitudes about family traditions and history, about sharing stories, and about their values and wishes. Not
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    that the estate tax laws aren't important, because they are. It's just that they're not going to motivate many people who just don't care about such things.

    That seems to be in accord with the findings of the Allianz American Legacies Study.
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    n that study, it was found that "[t]he top qualities both generations look for in a legacy advisor are honesty, trustworthiness, compassion, a good listener and a strong and clear communicator."

    So there you have it! If you haven't taken the
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    time to have your estate planning done, it may be because your focus was on money. Instead, try focusing on your family and all the things that you love and cherish. You might find that you're suddenly anxious to find a legacy advisor that wil
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    make your estate planning experience a very memorable one. You're family will love you all the more for it.

    Just one more thing! According to the Allianz American Legacies Study, it is estimated by Paul Schervish and John J. Havens of the Bo
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    ston College Center on Wealth and Philanthropy that $41 trillion is set to be willed, passed on, and/or left to others over the next 50 years. So, even though we don't like to talk about it, it is an integral part of everyone's estate planning


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.advicepool.org.ua/article/129054/advicepool-Say-What--You-Dont-Have-An-Estate-Plan----.html">Say What? You Don't Have An Estate Plan . . . !</a>

    BB link (for phorums):
    [url=http://www.advicepool.org.ua/article/129054/advicepool-Say-What--You-Dont-Have-An-Estate-Plan----.html]Say What? You Don't Have An Estate Plan . . . ![/url]

    Related Articles:

    How These Famous Entrepreneurs Can Teach and Inspire Us

    What Is An Autoresponder Service And How It Differs From An Autoresponder Software

    Your Accountant Will Agree: Leasing a Car For Your Business is the Way To Go

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com